These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28497200)

  • 21. Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.
    Barbagallo I; Giallongo C; Volti GL; Distefano A; Camiolo G; Raffaele M; Salerno L; Pittalà V; Sorrenti V; Avola R; Di Rosa M; Vanella L; Di Raimondo F; Tibullo D
    Mol Neurobiol; 2019 Feb; 56(2):1451-1460. PubMed ID: 29948946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca
    Lee AR; Seo MJ; Kim J; Lee DM; Kim IY; Yoon MJ; Hoon H; Choi KS
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
    Loi M; Becherini P; Emionite L; Giacomini A; Cossu I; Destefanis E; Brignole C; Di Paolo D; Piaggio F; Perri P; Cilli M; Pastorino F; Ponzoni M
    J Control Release; 2014 Oct; 192():157-66. PubMed ID: 25041999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced response of IRE1α/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
    Xu X; Liu J; Huang B; Chen M; Yuan S; Li X; Li J
    Tumori; 2017 May; 103(3):261-267. PubMed ID: 27647225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
    Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
    Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis.
    Lee HM; Lee E; Yeo SY; Shin S; Park HK; Nam DH; Kim SH
    Invest New Drugs; 2018 Aug; 36(4):545-560. PubMed ID: 29349597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
    Li C; Hu J; Li W; Song G; Shen J
    Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma.
    Ri M
    Int J Hematol; 2016 Sep; 104(3):273-80. PubMed ID: 27169614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
    Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
    Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines.
    Du BY; Song W; Bai L; Shen Y; Miao SY; Wang LF
    Chemotherapy; 2012; 58(1):44-51. PubMed ID: 22327308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elaidic acid induces cell apoptosis through induction of ROS accumulation and endoplasmic reticulum stress in SH‑SY5Y cells.
    Ma WW; Zhao L; Yuan LH; Yu HL; Wang H; Gong XY; Wei F; Xiao R
    Mol Med Rep; 2017 Dec; 16(6):9337-9346. PubMed ID: 29152653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells.
    Choi AY; Choi JH; Yoon H; Hwang KY; Noh MH; Choe W; Yoon KS; Ha J; Yeo EJ; Kang I
    Eur J Pharmacol; 2011 Oct; 668(1-2):115-26. PubMed ID: 21762691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib as a therapeutic candidate for neuroblastoma.
    Armstrong MB; Schumacher KR; Mody R; Yanik GA; Opipari AW; Castle VP
    J Exp Ther Oncol; 2008; 7(2):135-45. PubMed ID: 18771087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of tyrosine kinase receptor B and brain-derived neurotrophic factor on chemoresistance in neuroblastoma].
    Li AM; Zhang JH; Zhang JH; Zhang KR; Rong DJ
    Zhonghua Er Ke Za Zhi; 2006 Jul; 44(7):535-9. PubMed ID: 17044982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
    Lipchick BC; Utley A; Han Z; Moparthy S; Yun DH; Bianchi-Smiraglia A; Wolff DW; Fink E; Liu L; Furdui CM; Lee J; Lee KP; Nikiforov MA
    Blood Adv; 2021 Apr; 5(7):1933-1946. PubMed ID: 33821992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotective effects of propofol on ER stress-mediated apoptosis in neuroblastoma SH-SY5Y cells.
    Nakajima A; Tsuji M; Inagaki M; Tamura Y; Kato M; Niiya A; Usui Y; Oguchi K
    Eur J Pharmacol; 2014 Feb; 725():47-54. PubMed ID: 24444437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.
    Fink EE; Mannava S; Bagati A; Bianchi-Smiraglia A; Nair JR; Moparthy K; Lipchick BC; Drokov M; Utley A; Ross J; Mendeleeva LP; Savchenko VG; Lee KP; Nikiforov MA
    Leukemia; 2016 Jan; 30(1):104-11. PubMed ID: 26205085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway.
    Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW
    Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.